Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Thermo Fisher agrees to buy genetic tester Qiagen in $11.5 billion deal

Stock MarketsMar 03, 2020 12:49PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. Illustration of products are pictured from Qiagen, the diagnostics company which has agreed an $11.5 billion takeover deal with U.S-based Thermo Fisher

By Christoph Steitz, Ludwig Burger and Rebecca Spalding

FRANKFURT/NEW YORK (Reuters) - Thermo Fisher Scientific Inc (N:TMO) said on Tuesday it agreed to acquire German genetic testing company Qiagen NV (DE:QIA) (N:QGEN) in an $11.5 billion deal as the U.S.-based company looks to bolster its health diagnostic business.

Qiagen, which has its main operations in Germany but is headquartered in the neighbouring Netherlands, is one of the world's largest suppliers of products to prepare tissue and blood samples for advanced testing.

These genetic tests play a major role in research and treatment of cancer, infectious diseases and genetic disorders.

Last month it also began shipping a new rapid testing kit for the coronavirus to hospitals in China. The outbreak has claimed more than 3,000 lives and infected more than 90,000 people globally, after spreading from China to 77 other countries and territories

At 39 euros per share, Thermo Fisher's cash offer was accepted at a 23% premium to Qiagen's closing price on Monday, Qiagen said, adding that the bid valued the company at 10.4 billion euros ($11.5 billion), including 1.26 billion euros in net debt.

Qiagen shares rose 18% on the news to 37.5 euros, on track for their best daily gain in two decades.Thermo Fisher, which has a market valuation of around $120 billion, is the leading maker of instruments, software and other services for scientific research, including the vaccines and diagnostic tests now under development to combat coronavirus.

Thermo Fisher fist approached Qiagen about a potential takeover last year, according to people familiar with the matter who asked not to be identified because the details are confidential.

In December, Qiagen ended the talks because it was not satisfied with the price offered and harbored concerns about the deal getting past antitrust regulators, one of the sources added.

Marc Casper, Thermo Fisher's chief executive officer, said that the instrumentation giant had long considered Qiagen a potential strategic partner. Qiagen's coronavirus testing capabilities were not a significant part of the deal's rationale, he added."Deals happen when they happen," Casper said in an interview. "When we got into the last few weeks, things really accelerated here. We were able to come to a price and deal terms that both companies felt are compelling."

Shares in Thermo Fisher rose 3.5% to $315.50 a share in trading on the New York Stock Exchange.

The deal was the second to be announced this week in the healthcare sector, illustrating how some companies are braving the current market volatility to pursue deals. On Monday, Gilead Sciences Inc (O:GILD) said it would buy smaller biotechnology company Forty Seven Inc (O:FTSV) for its research in immuno-oncology in a $4.9 billion deal.


The acquisition of Qiagen, which is expected to be completed in the first half of 2021, will immediately add to Thermo Fisher's earnings after the deal closes, the companies said.

Thermo Fisher said the deal would generate $200 million in savings by three years after the deal's close.

Jefferies analysts said they had long viewed Qiagen's strong position in research labs, plus front-end prep for molecular diagnostics as attractive to larger life science conglomerates.

For Qiagen, the deal comes after a tumultuous few months. The company's long-serving CEO Peer Schatz resigned in October when it announced a reversal of its strategy, saying it would stop developing its next-generation genome sequencing machines and instead collaborate with industry leader Illumina (O:ILMN).

JPMorgan (N:JPM) and Morgan Stanley (N:MS) served as financial advisers to Thermo Fisher, while Wachtell, Lipton, Rosen & Katz provided legal counsel.

For Qiagen, Goldman Sachs (N:GS) is lead financial advisor and Barclays (L:BARC) is serving as financial adviser, while De Brauw Blackstone (NYSE:BX) Westbroek NV, Linklaters LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C. are serving as legal counsel.

Thermo Fisher agrees to buy genetic tester Qiagen in $11.5 billion deal

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email